Investment Thesis
Oric is a development-stage pharmaceutical company with no reported revenue and significant operating losses of -$39.6M annually. Despite a strong balance sheet with $56.4M in cash and minimal debt, the company faces approximately 1.7-2 years of cash runway at current burn rates. Success is entirely dependent on undisclosed pipeline milestones and regulatory approval outcomes.
Strengths
- Exceptional balance sheet with 16.33x current ratio and minimal debt (Debt/Equity 0.03x)
- Low financial leverage provides substantial flexibility for continued R&D investment
- Diluted EPS improved 19.7% YoY, indicating cost management and operational discipline
Risks
- Pre-revenue stage with no commercial products generating positive cash flow
- Negative operating cash flow of -$32.4M annually limits financial runway to approximately 1.7-2 years
- Pipeline-dependent business model with unknown clinical trial progress, regulatory approval timeline, and commercialization prospects
Key Metrics to Watch
- Operating cash burn rate and updated cash runway analysis
- Clinical trial milestone announcements and regulatory approval status
- Revenue recognition or product commercialization timeline
Financial Metrics
Revenue
N/A
Net Income
-35.8M
EPS (Diluted)
$-0.34
Free Cash Flow
-32.4M
Total Assets
436.8M
Cash
56.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-8.6%
ROA
-8.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
16.33x
Quick Ratio
16.33x
Debt/Equity
0.03x
Debt/Assets
4.9%
Interest Coverage
N/A
Long-term Debt
10.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:47:34.192203 |
Data as of: 2026-03-31 |
Powered by Claude AI